2. Search Result
Search Result
Results for "

Peripheral Nervous System

" in MedChemExpress (MCE) Product Catalog:

62

Inhibitors & Agonists

1

Screening Libraries

17

Peptides

1

MCE Kits

1

Inhibitory Antibodies

6

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1071
    α-CGRP (human)
    4 Publications Verification

    Calcitonin gene-related peptide

    		 CGRP Receptor Cardiovascular Disease
    α-CGRP (human) (Calcitonin gene-related peptide) is a regulatory neuropeptide of 37 amino acids. α-CGRP (human) is widely distributed in the central and peripheral nervous system. α-CGRP (human) is a potent vasodilator and has inotropic and chronotropic effects .
    α-CGRP (human)
  • HY-B0002B
    Ondansetron
    5+ Cited Publications

    GR 38032; SN 307

    		 5-HT Receptor Neurological Disease
    Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .
    Ondansetron
  • HY-12560A
    PNU-282987
    Maximum Cited Publications
    14 Publications Verification

    		 nAChR 5-HT Receptor Neurological Disease
    PNU-282987 is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems .
    PNU-282987
  • HY-P99221
    Tanezumab

    RN-624; PF 4383119

    		 Trk Receptor Neurological Disease Inflammation/Immunology Cancer
    Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
    Tanezumab
  • HY-P1944
    Apelin-13
    Maximum Cited Publications
    10 Publications Verification

    		 Apelin Receptor (APJ) Cardiovascular Disease Metabolic Disease
    Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .
    Apelin-13
  • HY-B0002
    Ondansetron hydrochloride
    5+ Cited Publications

    GR 38032 hydrochloride; SN 307 hydrochloride

    		 5-HT Receptor Neurological Disease
    Ondansetron (GR 38032; SN 307) hydrochloride is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron hydrochloride exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .
    Ondansetron hydrochloride
  • HY-108652
    α,β-Methylene-ATP trisodium
    1 Publications Verification

    		 P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP trisodium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP trisodium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP trisodium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP trisodium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP trisodium
  • HY-B0002A
    Ondansetron hydrochloride dihydrate
    5+ Cited Publications

    GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate

    		 5-HT Receptor Neurological Disease
    Ondansetron (GR 38032; SN 307) hydrochloride dehydrate is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron hydrochloride dehydrate exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron hydrochloride dehydrate can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .
    Ondansetron hydrochloride dihydrate
  • HY-B0206
    Rizatriptan benzoate

    MK 462

    		 5-HT Receptor Neurological Disease
    Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
    Rizatriptan benzoate
  • HY-P1248
    Neuropeptide FF

    NPFF

    		 Neuropeptide FF Receptor Cardiovascular Disease Neurological Disease
    Neuropeptide FF (NPFF), an octapeptide belonging to the RF-amide family of peptides, is a NPFF1 and NPFF2 receptors agonist with Ki values of 2.82 nM and 0.21 nM, respectively. Neuropeptide FF induces abstinence syndrome, exerts antiopioid and analgesic effects, releases via calcium-dependent mechanisms from rat spinal cord, regulates memory, autonomic function, and neuroendocrine function, modulates pain and opioid antinociception, reduces food intake, stimulates water intake, alters cardiovascular parameters, and shows differential activity in hypothalamic paraventricular nucleus neurons. Neuropeptide FF is present in mammalian central nervous system and periphery, with NPFF-immunoreactivity increases in rat cerebrospinal fluid during opiate tolerance, and its NPFF gene and NPFF-R2 gene are up-regulated in rat spinal cord and dorsal root ganglia during peripheral inflammation. Neuropeptide FF can be used for the research of opioid tolerance, morphine-induced analgesia, abstinence syndrome, pain, hypertension, nociception, inflammatory pain, and neuropathic pain .
    Neuropeptide FF
  • HY-P4058
    Calcitonin gene-related peptide free acid
    1 Publications Verification

    CGRP free acid

    		 CGRP Receptor Neurological Disease
    Calcitonin gene-related peptide (CGRP) free acid is a 37-amino acid neuropeptide, which represents the deamidated form of α-CGRP (human) (HY-P1071). Calcitonin gene-related peptide free acid is produced in the central and peripheral nervous systems of rats, and localizes to specific sensory, integrative and motor neuron systems, including those involved in nociception/thermoreception, feeding behavior, olfaction and visceral motor functions .
    Calcitonin gene-related peptide free acid
  • HY-16723
    Funapide

    TV 45070; XEN402

    		 Sodium Channel Neurological Disease Inflammation/Immunology
    Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC50 values ??of 84 nM and 54 nM for Nav1.5 and Nav1.7, respectively. Funapide has analgesic effects .
    Funapide
  • HY-P0244
    Dermorphin

    		Opioid Receptor Neurological Disease
    Dermorphin is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .
    Dermorphin
  • HY-P1071A
    α-CGRP (human) TFA
    4 Publications Verification

    Calcitonin gene-related peptide TFA

    		 CGRP Receptor Cardiovascular Disease
    α-CGRP (human) (TFA) is a regulatory neuropeptide of 37 amino acids. α-CGRP (human) (TFA) is widely distributed in the central and peripheral nervous system. α-CGRP (human) (TFA) is a potent vasodilator and has inotropic and chronotropic effects .
    α-CGRP (human) TFA
  • HY-P3609
    CR 665
    2 Publications Verification

    JNJ 38488502; FE 200665

    		 Opioid Receptor Neurological Disease
    CR 665 (JNJ 38488502) is a peripherally selective κ-opioid agonist. CR 665 can activate the kappa opioid receptor with EC50 value of 10.9 nM. CR 665 can be used for the research of peripheral pain .
    CR 665
  • HY-B1032
    Dropropizine

    (±)-Dropropizine; UCB-196

    		 Histamine Receptor Neurological Disease
    Dropropizine ((±)-Dropropizine; UCB-196) is an orally effective, peripherally selective antitussive that inhibits the activity of peripheral receptors and afferent nerves in the respiratory tract. Dropropizine acts on the cough reflex pathway, does not pass the blood-brain barrier, and has no central nervous system side effects. Dropropizine mainly regulates the level of sensory neuropeptides and inhibits the afferent signal transmission of the cough reflex, thereby alleviating the symptoms of dry cough, and has both mild local anesthetic and antihistamine activity. Dropropizine is mainly used for symptomatic research on dry cough caused by respiratory diseases .
    Dropropizine
  • HY-N0746
    Oxysophocarpine
    5+ Cited Publications

    		 Others Cancer
    Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides.?Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the?growth?and?metastasis?of ?oral?squamous?cell?carcinoma?(OSCC) .
    Oxysophocarpine
  • HY-134440A
    α,β-Methylene-ATP

    		P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP
  • HY-P3019
    Urocortin III (human)

    		CRFR Cardiovascular Disease Neurological Disease Endocrinology
    Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF2β (Ki = 13.5 nM) and rCRF2α (Ki = 21.7 nM), while demonstrating negligible affinity for hCRF1 (Ki >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion [1][2].
    Urocortin III (human)
  • HY-160092A
    Martinostat hydrochloride

    		HDAC Neurological Disease
    Martinostat hydrochloride is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .
    Martinostat hydrochloride
  • HY-164495
    Sob-AM2

    		FAAH Thyroid Hormone Receptor Inflammation/Immunology Endocrinology
    Sob-AM2 is a potent substrate (Km=1.3 μM) targeting fatty acid amide hydrolase (FAAH) expressed in the brain and has blood-brain barrier permeability. Sob-AM2 delivers high concentrations of Sobetirome (HY-14823) to the central nervous system with minimal peripheral systemic dose, thereby stimulating central thyroid hormone receptor β (TRβ). In addition, Sob-AM2 can prevent myelin and axon degeneration in experimental autoimmune encephalomyelitis (EAE) mice .
    Sob-AM2
  • HY-164049
    TG8-260

    		Prostaglandin Receptor Inflammation/Immunology
    TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
    TG8-260
  • HY-108960
    PPADS

    		P2X Receptor Interleukin Related Neurological Disease
    PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .
    PPADS
  • HY-P3019A
    Urocortin III (human) TFA

    		CRFR Cardiovascular Disease Neurological Disease Metabolic Disease
    Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF2β (Ki = 13.5 nM) and rCRF2α (Ki = 21.7 nM), while demonstrating negligible affinity for hCRF1 (Ki >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .
    Urocortin III (human) TFA
  • HY-134173
    Arachidonoyl ethanolamide phosphate

    		Cannabinoid Receptor Apoptosis Neurological Disease
    Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype) .
    Arachidonoyl ethanolamide phosphate
  • HY-16723A
    (R)-Funapide

    (R)-TV 45070; (R)-XEN402

    		 Sodium Channel Neurological Disease Inflammation/Immunology
    (R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel Nav1.7, Nav1.8 and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .
    (R)-Funapide
  • HY-14790
    Esreboxetine

    (S,S)-(+)-Reboxetine

    		 Adrenergic Receptor Neurological Disease
    Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain .
    Esreboxetine
  • HY-161712
    IMPDH-IN-4

    		IMPDH Cancer
    IMPDH-IN-4 is a derivative of N-pyridinylthiophene carboxamid that exhibits activity against peripheral nerve sheath carcinoma cells. IMPDH-IN-4 is metabolized by NAMPT and NMNAT1 to an adenine dinucleotide (AD) derivative, which is an NAD analog and can inhibit inosine monophosphate dehydrogenase (IMPDH), leading to the accumulation of inosine monophosphate (IMP) in cells. IMPDH-IN-4 has good blood-brain barrier permeability and can be used in the study of central and peripheral nervous system cancers .
    IMPDH-IN-4
  • HY-164728
    Pregabalin diacid

    		Calcium Channel Neurological Disease
    Pregabalin diacid is an impurity of Pregabalin, a lipophilic GABA (γ-aminobutyric acid) analog with anxiolytic and anticonvulsant activity. Pregabalin may act on the α(2)β subunit of voltage-dependent calcium channels, which are widely distributed in the peripheral and central nervous systems. Pregabalin can effectively induce hypoalgesia and improve behavioral disorders .
    Pregabalin diacid
  • HY-B0002BS
    Ondansetron-d5

    GR 38032-d5; SN 307-d5

    		 5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Ondansetron-d5 is the deuterium labeled Ondansetron (HY-B0002B). Ondansetron (GR 38032; SN 307) is a highly selective 5-HT3 receptor antagonist with an IC50 value of 103 pM. Ondansetron exerts its antiemetic effect by antagonizing 5-HT receptors located in localized neurons in the peripheral and central nervous systems. Ondansetron can inhibit nausea and vomiting induced by chemotherapy and radiotherapy .
    Ondansetron-d5
  • HY-12560
    PNU-282987 free base

    		nAChR 5-HT Receptor Neurological Disease
    PNU-282987 (free base) is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC50 of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT3 receptor with an IC50 of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems .
    PNU-282987 free base
  • HY-19057
    Vatinoxan
    2 Publications Verification

    MK-467; L-659066

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .
    Vatinoxan
  • HY-160092
    Martinostat

    		HDAC Neurological Disease
    Martinostat is a HDAC inhibitor and can be labeled with radionuclides for quantitative imaging of HDACs in vivo in the central nervous system and major peripheral organs .
    Martinostat
  • HY-122281
    JTE 7-31

    		Cannabinoid Receptor Others
    JTE 7-31 selectively acts on peripheral cannabinoid receptors, minimizing central nervous system side effects. They exhibit potent immunomodulatory, anti-inflammatory and anti-allergic properties, as well as inhibitory effects on nephritis .
    JTE 7-31
  • HY-N0746R
    Oxysophocarpine (Standard)

    		Reference Standards Others Cancer
    Oxysophocarpine (Standard) is the analytical standard of Oxysophocarpine. This product is intended for research and analytical applications. Oxysophocarpine is an alkaloid extracted from Sophora alopecuroides. Oxysophocarpine has neuroprotective and anti-nociceptive effects on the central and peripheral nervous systems . Oxysophocarpine inhibits the growth and metastasis of oral squamous cell carcinoma (OSCC) .
    Oxysophocarpine (Standard)
  • HY-B0206R
    Rizatriptan benzoate (Standard)

    MK 462 (Standard)

    		 Reference Standards 5-HT Receptor Neurological Disease
    Rizatriptan (benzoate) (Standard) is the analytical standard of Rizatriptan (benzoate). This product is intended for research and analytical applications. Rizatriptan benzoate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan benzoate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
    Rizatriptan benzoate (Standard)
  • HY-P2719
    Fibronectin Type III Connecting Segment Fragment 1-25

    		Integrin Neurological Disease
    Fibronectin Type III Connecting Segment Fragment 1-25 is a peptide that is responsible for melanoma cell adhesion, and plays an important role in development of the peripheral nervous system in chicken .
    Fibronectin Type III Connecting Segment Fragment 1-25
  • HY-163855
    KGP-25

    		Sodium Channel GABA Receptor Neurological Disease
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia .
    KGP-25
  • HY-P0244A
    Dermorphin TFA

    		Opioid Receptor Neurological Disease
    Dermorphin TFA is a natural heptapeptide μ-opioid receptor (MOR) agonist found in amphibian skin. Inhibition of neuropathic pain .
    Dermorphin TFA
  • HY-134440
    α,β-Methylene-ATP dilithium

    		P2X Receptor Inflammation/Immunology
    α,β-Methylene-ATP dilithium is an agonist of P2X1 and P2X3 receptors and can cross the blood-brain barrier. α,β-Methylene-ATP dilithium can trigger a reflex pressor response by activating P2X receptors in peripheral muscles and the central locus coeruleus (LC); this effect can be blocked by the P2X antagonist PPADS (HY-108960). α,β-Methylene-ATP dilithium also activates noradrenergic neurons in the central locus coeruleus, mediating antinociceptive effects; this effect can be attenuated by the locus coeruleus damaging agent DSP-4 (HY-103210/HY-121602). α,β-Methylene-ATP dilithium can be used to study the pathological mechanisms of neuropathic pain, cardiovascular reflex regulation, and antinociceptive effects of the central nervous system .
    α,β-Methylene-ATP dilithium
  • HY-131728
    GPR35 agonist 3

    		GPR35 Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50value of 1.4 μM. GPR35 agonist 3 can be used for the research of various diseases, such as gastric cancer, type 2 diabetes, cardiovascular diseases, immune system and peripheral nervous system .
    GPR35 agonist 3
  • HY-N8693
    Withanoside IV

    		COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV Infection Neurological Disease
    Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
    Withanoside IV
  • HY-P1253
    α-Endorphin (human)

    		Opioid Receptor Neurological Disease
    α-Endorphin (human) is a neuropeptide, that acts on the central nervous system (CNS) and peripheral nervous system (PNS). α-Endorphin (human) binds μ-opioid receptor, and exhibits analgesic efficacy. α-Endorphin (human) regulates sexual behaviors and pleasure felling .
    α-Endorphin (human)
  • HY-106147
    Frakefamide

    		Opioid Receptor Neurological Disease
    Frakefamide is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .
    Frakefamide
  • HY-106147B
    Frakefamide TFA

    		Opioid Receptor Neurological Disease
    Frakefamide TFA is a potent analgesic that acts as a peripheral active μ-selective receptor agonist. Frakefamide is unable to penetrate the blood-brain-barrier and enter the central nervous system .
    Frakefamide TFA
  • HY-121670
    Ambenoxan

    		Others Neurological Disease
    Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan
  • HY-121670A
    Ambenoxan hydrochloride

    		Adrenergic Receptor Neurological Disease
    Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan hydrochloride
  • HY-P10110
    retro-inverso TAT-Beclin 1 (D-amino acid)

    		Autophagy Neurological Disease
    retro-inverso TAT-Beclin 1 D-amino acid is has higher activity and resistance to proteolytic degradation in vivo compared to L-amino acids peptide. TAT-Beclin 1 can induce autophagy in peripheral tissues in adult mice as well as in the central nervous system of neonatal mice .
    retro-inverso TAT-Beclin 1 (D-amino acid)
  • HY-W018475B
    Rizatriptan hemisulfate hemihydrate

    MK 462 hemisulfate hemihydrate

    		 5-HT Receptor Neurological Disease
    Rizatriptan (MK 462) hemisulfate hemihydrate is the agonist for 5-HT1B and 5-HT1D. Rizatriptan hemisulfate hemihydrate has a peripheral vasoconstrictive effect, penetrates the intact blood-brain barrier, and inhibits pain neurotransmission in the central nervous system .
    Rizatriptan hemisulfate hemihydrate
  • HY-130670
    CGP 54626

    		GABA Receptor Neurological Disease
    CGP 54626 is a GABAB receptor modulator, which is essential in the central and peripheral nervous systems. It is used as a tool to identify and characterize GABAB receptor agonists and antagonists, which will aid in the development of drugs targeting diseases related to these systems. This discovery involves purified GABAB receptors, receptor proteins and their encoding nucleic acids, facilitating the study of new members of the GABAB receptor family through DNA cloning technology and sequence-derived probes .
    CGP 54626

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: